ACT 077825
Alternative Names: Act-AAALatest Information Update: 27 Jun 2017
At a glance
- Originator Actelion Pharmaceuticals; Merck & Co
- Developer Actelion Pharmaceuticals
- Class Cardiovascular therapies
- Mechanism of Action Renin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cardiovascular disorders
Most Recent Events
- 16 Jun 2017 Actelion Pharmaceuticals was acquired by Janssen Pharmaceuticals
- 19 Jul 2012 Merck and Actelion terminate their collaboration in renin inhibitors
- 18 Mar 2005 Actelion achieved its second milestone in regard to the renin alliance with Merck & Co and has moved its first compound into full preclinical development